Arab Drug Company for Pharmaceuticals and Chemical Industries SAE

Arab Drug Company for Pharmaceuticals and Chemical Industries SAE maintains a debt-to-equity ratio of 1.19, indicating a moderate level of leverage. The company's liquidity is assessed as medium, with a current ratio of 2.46, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow is negative at -13.98 million EGP, which may signal reinvestment in the business or operational inefficiencies.

Profitability metrics show a return on equity of 3.8% and a return on assets of 1.53%, both below the typical thresholds for strong performance in the pharmaceutical industry. These figures suggest the company is generating modest returns relative to its equity and asset base, which may indicate challenges in optimizing capital efficiency or pricing power.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts, which could impact revenue stability. No major geographic markets are disclosed, but the company's operations are likely centered in Egypt given the currency of its financials.

Growth trajectory is constrained by the company's negative free cash flow and limited capital expenditure of -253.47 million EGP. While this may reflect strategic reinvestment, it also suggests a lack of expansion or innovation investment. Revenue growth is not explicitly forecasted, but the company's operating cash flow of 145.88 million EGP indicates some capacity to fund operations and debt obligations.

Risk factors include a medium liquidity risk due to the company's current ratio and negative free cash flow. The company's debt load, particularly its long-term debt of 525.87 million EGP, is a significant portion of its total liabilities. Dilution risk is assessed as low, with no recent or disclosed share issuance or dilutive events. However, the company's net cash position is negative after subtracting total debt, which could necessitate future financing.

Recent events include the latest financial filing, which provides a snapshot of the company's financial position as of the most recent reporting period. No recent earnings call transcripts or major regulatory filings are disclosed, limiting insight into management's strategic direction or operational updates.

Revenue surged 42.3% year-over-year to 1.12 billion EGP, demonstrating strong top-line growth momentum.

Net income more than doubled with a 121.6% year-over-year increase, reaching 227.9 million EGP.

Operating income jumped 164.1% year-over-year to 311.9 million EGP, indicating significant operational leverage.

Cash conversion ratio of 8.67 is best-in-class compared to the cohort median of 0.95.

Debt-to-equity ratio of 1.19 is in the bottom quartile, far exceeding the cohort median of 0.18.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations.

Return on equity of 3.8% remains low despite revenue growth, suggesting inefficient capital utilization.

Capex to revenue ratio of -1.52 is in the bottom quartile, indicating heavy capital intensity.

Medium liquidity risk flags potential challenges in managing short-term financial obligations effectively.

Revenue EGP 785.5M, +23,9% YoY; Operating income +24,6% YoY.

• ▍Revenue EGP 785.5M, +23,9% YoY
• ▍Operating income +24,6% YoY
• ▍Net income +24,2% YoY
• ▍Free cash flow −1 724,8% YoY
• ▍Net margin 13.1%

Revenue EGP 633.7M, +25,5% YoY; Operating income +9,8% YoY.

• ▍Revenue EGP 633.7M, +25,5% YoY
• ▍Operating income +9,8% YoY
• ▍Net income +8,5% YoY
• ▍Free cash flow +83,7% YoY
• ▍Net margin 13.1%

Revenue EGP 505.0M, −6,0% YoY; Operating income −29,4% YoY.

• ▍Revenue EGP 505.0M, −6,0% YoY
• ▍Operating income −29,4% YoY
• ▍Net income −24,8% YoY
• ▍Free cash flow −209,9% YoY
• ▍Net margin 15.1%

Revenue EGP 537.0M; Operating income EGP 122.2M.

• ▍Revenue EGP 537.0M
• ▍Operating income EGP 122.2M
• ▍Net margin 18.9%